{"id":"https://openalex.org/W2056734036","doi":"https://doi.org/10.1097/00130404-200209000-00010","title":"A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal Cancer","display_name":"A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal Cancer","alternate_titles":[],"publication_year":2002,"publication_date":"2002-09-01","ids":{"openalex":"https://openalex.org/W2056734036","doi":"https://doi.org/10.1097/00130404-200209000-00010","mag":"2056734036","pmid":"https://pubmed.ncbi.nlm.nih.gov/12416897"},"language":"en","primary_location":{"id":"doi:10.1097/00130404-200209000-00010","doi":"https://doi.org/10.1097/00130404-200209000-00010","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00130404-200209000-00010","pdf_url":null,"source":{"id":"https://openalex.org/S4210176243","display_name":"The Cancer Journal","issn_l":"1528-9117","issn":["1528-9117","1540-336X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Cancer Journal","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2056734036"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017947396","display_name":"Matthew H. Kulke","orcid":"https://orcid.org/0000-0001-8556-3977","observed_orcids":["https://orcid.org/0000-0001-8556-3977"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Matthew H. Kulke","raw_affiliation_strings":["Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060580923","display_name":"George D. Demetri","orcid":"https://orcid.org/0000-0002-0045-4809","observed_orcids":["https://orcid.org/0000-0002-0045-4809"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George D. Demetri","raw_affiliation_strings":["Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","Dana Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007260460","display_name":"Norman E. Sharpless","orcid":"https://orcid.org/0000-0001-7078-9455","observed_orcids":["https://orcid.org/0000-0001-7078-9455"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Norman E. Sharpless","raw_affiliation_strings":["Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","Lineberger Comprehensive Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center","institution_ids":["https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070720153","display_name":"David P. Ryan","orcid":"https://orcid.org/0000-0002-9685-673X","observed_orcids":["https://orcid.org/0000-0002-9685-673X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David P. Ryan","raw_affiliation_strings":["Department of Oncology, Massachusetts General Hospital, Boston, Massachusetts","Harvard University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Massachusetts General Hospital, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Harvard University","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055619783","display_name":"Ramesh A. Shivdasani","orcid":"https://orcid.org/0000-0002-2828-1727","observed_orcids":["https://orcid.org/0000-0002-2828-1727"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ramesh Shivdasani","raw_affiliation_strings":["Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","Dana Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jeffrey S. Clark","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey S. Clark","raw_affiliation_strings":["Department of Oncology, Massachusetts General Hospital, Boston, Massachusetts","Harvard University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Massachusetts General Hospital, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Harvard University","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022918796","display_name":"Bruce M. Spiegelman","orcid":"https://orcid.org/0000-0002-7658-4802","observed_orcids":["https://orcid.org/0000-0002-7658-4802"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce M. Spiegelman","raw_affiliation_strings":["Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","Dana Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014155836","display_name":"Haesook T. Kim","orcid":"https://orcid.org/0000-0003-4889-6849","observed_orcids":["https://orcid.org/0000-0003-4889-6849","https://orcid.org/0000-0002-4693-0911"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haesook Kim","raw_affiliation_strings":["Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","Dana Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055389521","display_name":"Robert James Mayer","orcid":"https://orcid.org/0000-0002-0484-2876","observed_orcids":["https://orcid.org/0000-0002-0484-2876"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert J. Mayer","raw_affiliation_strings":["Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","Dana Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049314303","display_name":"Charles S. Fuchs","orcid":"https://orcid.org/0000-0003-1582-9842","observed_orcids":["https://orcid.org/0000-0003-1582-9842"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles S. Fuchs","raw_affiliation_strings":["Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","Dana Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5017947396"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":2.2639,"has_fulltext":false,"cited_by_count":169,"citation_normalized_percentile":{"value":0.88118781,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"8","issue":"5","first_page":"395","last_page":"399"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.8827999830245972,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.8827999830245972,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.11150000244379044,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12465","display_name":"Cancer, Lipids, and Metabolism","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/troglitazone","display_name":"troglitazone","score":1.0},{"id":"https://openalex.org/keywords/ppargamma","display_name":"PPAR\u03b3","score":0.847000002861023},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/chemoresistance","display_name":"chemoresistance","score":0.8980000019073486},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.5400000214576721},{"id":"https://openalex.org/keywords/tumor-differentiation","display_name":"tumor differentiation","score":0.6190000176429749},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.75},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8370000123977661},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.36399999260902405}],"concepts":[{"id":"https://openalex.org/C2778150266","wikidata":"https://www.wikidata.org/wiki/Q7844989","display_name":"Troglitazone","level":4,"score":0.9427556991577148},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8372461795806885},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.8049356341362},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6205219030380249},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6164712309837341},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.610699474811554},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4631352722644806},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43027758598327637},{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.362322062253952},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3560956120491028}],"mesh":[{"descriptor_ui":"D000077288","descriptor_name":"Troglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002839","descriptor_name":"Chromans","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002839","descriptor_name":"Chromans","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014157","descriptor_name":"Transcription Factors","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017211","descriptor_name":"Treatment Failure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018160","descriptor_name":"Receptors, Cytoplasmic and Nuclear","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/00130404-200209000-00010","doi":"https://doi.org/10.1097/00130404-200209000-00010","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00130404-200209000-00010","pdf_url":null,"source":{"id":"https://openalex.org/S4210176243","display_name":"The Cancer Journal","issn_l":"1528-9117","issn":["1528-9117","1540-336X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Cancer Journal","raw_type":"journal-article"},{"id":"pmid:12416897","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12416897","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer journal (Sudbury, Mass.)","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W62075374","https://openalex.org/W1633340712","https://openalex.org/W1971432398","https://openalex.org/W1975160900","https://openalex.org/W1979300931","https://openalex.org/W1986163599","https://openalex.org/W2002519246","https://openalex.org/W2047982128","https://openalex.org/W2050352100","https://openalex.org/W2078535741","https://openalex.org/W2088144835","https://openalex.org/W2090553336","https://openalex.org/W2091321756","https://openalex.org/W2124084557","https://openalex.org/W2125090169","https://openalex.org/W2164015929","https://openalex.org/W2327237185","https://openalex.org/W3041047318"],"related_works":["https://openalex.org/W1968980738","https://openalex.org/W91831241","https://openalex.org/W2370296717","https://openalex.org/W1586597239","https://openalex.org/W2085579342","https://openalex.org/W3017364825","https://openalex.org/W2043620683","https://openalex.org/W2191185318","https://openalex.org/W1940540171","https://openalex.org/W1999063912"],"abstract_inverted_index":{"PURPOSE:":[0],"Troglitazone,":[1],"a":[2],"potent":[3],"activator":[4],"of":[5,19,37,42,66,132],"the":[6,35,40,115,130],"peroxisome":[7],"proliferator-activated":[8],"receptor-gamma,":[9],"induces":[10],"tumor":[11,68,88],"differentiation":[12],"in":[13,29,39,46],"human":[14,25],"liposarcomas":[15],"and":[16,70,92,114],"causes":[17],"regression":[18],"tumors":[20],"that":[21],"are":[22],"derived":[23],"from":[24],"colon":[26,44],"cancer":[27,45,54],"cells":[28],"nude":[30],"mice.":[31],"We":[32],"therefore":[33],"assessed":[34],"efficacy":[36],"troglitazone":[38],"treatment":[41,74,131],"metastatic":[43,52,133],"humans.":[47],"METHODS:":[48],"Twenty-five":[49],"patients":[50,95],"with":[51,57],"colorectal":[53,134],"were":[55,61,83,90],"treated":[56],"oral":[58],"troglitazone.":[59],"Patients":[60],"followed":[62],"up":[63],"for":[64,129],"evidence":[65],"toxicity,":[67],"response,":[69],"survival.":[71],"RESULTS:":[72],"The":[73,105],"was":[75,110,119],"well":[76],"tolerated:":[77],"no":[78,86],"grade":[79],"3/4":[80],"treatment-related":[81],"toxicities":[82],"observed.":[84],"However,":[85],"objective":[87],"responses":[89],"noted,":[91],"all":[93],"25":[94],"had":[96],"progressive":[97],"disease":[98],"as":[99],"their":[100],"best":[101],"response":[102],"to":[103],"therapy.":[104],"median":[106,116],"progression-free":[107],"survival":[108,117],"time":[109,118],"only":[111],"1.6":[112],"months,":[113],"3.9":[120],"months.":[121],"DISCUSSION:":[122],"Troglitazone":[123],"is":[124],"not":[125],"an":[126],"active":[127],"agent":[128],"cancer.":[135]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2056734036","counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":16}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
